COMP <GO>
AXSM vs ALKS // RETURN ON INVESTED CAPITAL (ROIC)
Axsome Therapeutics Inc. (NASDAQ) VS. Alkermes plc (NASDAQ) • 15-METRIC TALLY: AXSM 2
— ALKS 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ALKS
LAST: $136.01 (-5.83%) • MKT CAP: $7.57B
roic
-21.90%
LAST: $44.89 (-0.99%) • MKT CAP: $7.61B
roic
14.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. ALKS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | ALKS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 86.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -21.90% | 14.00% | -35.90 | ALKS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 25.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | 6.31% | -7.56 | ALKS | /fcf-yield <GO> |
| Operating Margin | -26.10% | 17.20% | -43.30 | ALKS | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 16.40% | -45.10 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | -5.20% | +70.70 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 8.03 | -2.69 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ALKS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.9 | 61.0 | -35.10 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.05 | +0.10 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 29.3x | +5.70 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.57B | $7.61B | -$41.0M | ALKS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | ALKS REV | AXSM GROSS % | ALKS GROSS % | AXSM FCF | ALKS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $1.48B | — | 86.7% | -$93.9M | $480.3M |
| FY 2024 | $385.7M | $1.56B | — | 84.2% | -$128.7M | $405.6M |
| FY 2023 | $270.6M | $1.66B | — | — | -$157.3M | $326.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
ALKS // BETA 1.05